
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934**

Date of Report (Date of earliest event reported) **November 4, 2009**

BECTON, DICKINSON AND COMPANY

(Exact Name of Registrant as Specified in Its Charter)

New Jersey

(State or Other Jurisdiction of Incorporation)

001-4802

(Commission File Number)

22-0760120

(IRS Employer Identification No.)

1 Becton Drive, Franklin Lakes, New Jersey

(Address of Principal Executive Offices)

07417-1880

(Zip Code)

(201) 847-6800

(Registrant's Telephone Number, Including Area Code)

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K Filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
-
-

ITEM 2.02 RESULTS OF OPERATIONS AND FINANCIAL CONDITION

On November 4, 2009, Becton, Dickinson and Company (“BD”) issued a press release announcing its financial results for its fourth fiscal quarter and fiscal year ending September 30, 2009. A copy of the press release is furnished as Exhibit 99.1 to this report.

The press release furnished as Exhibit 99.1 contains certain financial measures that differ from those presented in accordance with U.S. generally accepted accounting principles (“non-GAAP measures”). As described below, certain of these non-GAAP measures eliminate the effect of the charge relating to our pending settlement of certain antitrust class action suits (the “Litigation Charge”) and the tax benefit relating to various tax settlements (the “Tax Benefit”) that occurred in fiscal year 2009. In addition, during fiscal year 2009, the U.S. dollar strengthened significantly against most foreign currencies, primarily the Euro, compared to rates from fiscal year 2008. As a result, foreign currency translation impacted our operating results to a greater degree than we have typically experienced. Accordingly, certain non-GAAP measures eliminate the effect of foreign currency translation, including gains from our hedging activities.

- Revenues. We present international and total revenue growth rates (for the total company and each of its segments and business units, and for revenues relating to our safety-engineered devices) for the fourth quarter of fiscal year 2009 and for the full 2009 fiscal year at constant foreign exchange rates. We believe that this allows investors to better understand the underlying operating results of BD, thereby facilitating comparisons to prior periods.
- Gross Profit. We present gross profit for the fourth quarter of fiscal year 2009 and for the full 2009 fiscal year after eliminating the effect of foreign currency translation. Foreign currency translation caused our gross profit for these periods to be lower than it otherwise would have been. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD, and allows investors to more easily compare BD’s gross profit for these periods to other periods.
- Selling and Administrative Expense. We present selling and administrative expense for fiscal year 2009 (“Adjusted 2009 S&A”) after excluding the impact of the Litigation Charge. This charge caused our selling and administrative expense to be higher than it otherwise would have been, but is not considered by management to be part of ordinary operations. Accordingly, we believe that this adjusted measure of selling and administrative expense is more indicative of BD’s performance, and allows investors to more easily compare BD’s selling and administrative expense to other periods.

We also present selling and administrative expense for the fourth quarter of fiscal year 2009 and Adjusted 2009 S&A after eliminating the effect of foreign currency translation. Foreign currency translation caused our selling and administrative expense for these periods to be lower than it otherwise would have been. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD, and allows investors to more easily compare BD’s selling and administrative expense for these periods to other periods.

- Research and Development. We present research and development expense for the fourth quarter of fiscal year 2009 and for the full 2009 fiscal year after eliminating the effect of foreign currency translation. Foreign currency translation caused such expense for these periods to be lower than it otherwise would have been. We believe that
-

eliminating the effect of foreign currency translation allows investors to better understand our research and development expense, and allows investors to more easily compare BD's research and development expense for these periods to other periods.

- Operating Income. We present BD's operating income for fiscal year 2009 after excluding the impact of the Litigation Charge ("Adjusted 2009 Operating Income"). This charge caused our operating income to be lower than it otherwise would have been, but is not considered by management to be part of ordinary operations. Accordingly, we believe that this adjusted measure of operating income is more indicative of BD's performance, and allows investors to more easily compare BD's operating income to other periods.

We also present operating income for the fourth quarter of fiscal year 2009 and Adjusted 2009 Operating Income after eliminating the effect of foreign currency translation. Foreign currency translation caused our operating income for these periods to be either higher or lower (depending on the period) than it otherwise would have been. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD, and allow investors to more easily compare BD's operating income for these periods to other periods.

- Income Taxes and Effective Tax Rate. We present BD's income taxes ("Adjusted 2009 Income Tax") and effective tax rate for fiscal year 2009 after excluding the impact of the Litigation Charge and the Tax Benefit. These items caused our income taxes and effective tax rate for the period to be lower than they otherwise would have been, but are not considered by management to be part of ordinary operations. Accordingly, we believe that these adjusted measures of income taxes and effective tax rate are more indicative of BD's results, and allow investors to more easily compare BD's income taxes and effective tax rate for the period to other periods.

We also present income tax for the fourth quarter of fiscal year 2009 and Adjusted 2009 Income Tax after eliminating the effect of foreign currency translation. Foreign currency translation caused our income tax to be either higher or lower (depending on the period) than it otherwise would have been. We believe that eliminating the effect of foreign currency translation allows investors to better understand BD's income tax expense, and allows investors to more easily compare BD's income taxes for these periods to other periods.

- Income from Continuing Operations. We present BD's income from continuing operations for fiscal year 2009 after excluding the impact of the Litigation Charge and the Tax Benefit ("Adjusted 2009 Income from Continuing Operations"). These items caused income from continuing operations for the period to be lower than it otherwise would have been, but are not considered by management to be part of ordinary operations. Accordingly, we believe that this adjusted measure of income from continuing operations is more indicative of BD's underlying performance, and allows investors to more easily compare BD's operating income from continuing operations for the period to other periods.
-

We also present income from continuing operations for the fourth quarter of fiscal year 2009 and Adjusted 2009 Income from Continuing Operations after eliminating the effect of foreign currency translation. Foreign currency translation caused our income from continuing operations for these periods to be either higher or lower (depending on the period) than it otherwise would have been. We believe that eliminating the effect of foreign currency translation allows investors to better understand the underlying operating results of BD, and allows investors to more easily compare BD's income from continuing operations for these periods to other periods.

- Earnings Per Share from Continuing Operations We present BD's diluted earnings per share from continuing operations for fiscal year 2009 after excluding the impact of the Litigation Charge and the Tax Benefit ("Adjusted 2009 EPS"). These items caused our diluted earnings per share to be lower than it otherwise would have been, but are not considered by management to be part of ordinary operations. Accordingly, we believe that this adjusted measure of diluted earnings per share is more indicative of BD's performance, and allows investors to more easily compare BD's performance for the period to other periods.

We also present diluted earnings per share for the fourth quarter of fiscal year 2009 and Adjusted 2009 EPS after eliminating the effect of foreign currency translation. Foreign currency translation caused our diluted earnings per share for these periods to be either higher or lower (depending on the period) than it otherwise would have been. We believe that eliminating the effect of foreign currency translation for these periods allows investors to better understand the underlying operating results of BD, and facilitates comparisons to prior periods.

BD's management uses each of these non-GAAP measures in its own evaluation of BD's performance, particularly when comparing performance to past periods. Management also uses the non-GAAP results for budget planning purposes on a quarterly and annual basis.

BD provides non-GAAP measures to investors on a supplemental basis, as they provide additional insight into BD's financial results. Management believes the non-GAAP results provide a reasonable measure of BD's underlying performance before the effects of items that are considered by management to be outside of BD's underlying operational results or that affect period to period comparability.

Non-GAAP results should not be considered in isolation and are not in accordance with, or a substitute for, GAAP results. Our non-GAAP results may differ from similar measures used by other companies, even if similar terms are used to identify such measures. Although BD's management believes non-GAAP results are useful in evaluating the performance of its business, its reliance on these measures is limited since items excluded from such measures may have a material impact on BD's net income, earnings per share or cash flows calculated in accordance with GAAP. Therefore, management typically uses non-GAAP results in conjunction with GAAP results to address these limitations. Investors should also consider these limitations when evaluating BD's results.

A reconciliation of certain non-GAAP financial measures to the comparable GAAP measure is furnished as Exhibit 99.2 to this report.

Item 8.01 OTHER EVENTS

On October 19, 2009, Gen-Probe Incorporated (“Gen-Probe”) filed a patent infringement action against BD in the United States District Court for the Southern District of California. The complaint alleges that certain specimen collection products of BD infringe eight U.S. patents of Gen-Probe. Gen-Probe is seeking monetary damages and injunctive relief. We believe that we have meritorious defenses to this action and intend to defend this matter vigorously.

ITEM 9.01 FINANCIAL STATEMENTS AND EXHIBITS.

Exhibit 99.1 Press release dated November 4, 2009, which is furnished pursuant to Item 2.02

Exhibit 99.2 Reconciliation of non-GAAP financial measures, which is furnished pursuant to Item 2.02

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

BECTON, DICKINSON AND COMPANY
(Registrant)

By: /s/ Dean J. Parnicas
Dean J. Parnicas
Vice President, Corporate
Secretary and Public Policy

Date: November 4, 2009

Exhibit Index

- 99.1 Press release dated November 4, 2009, furnished pursuant to Item 2.02
- 99.2 Reconciliation of non-GAAP financial measures, furnished pursuant to Item 2.02

1 Becton Drive
Franklin Lakes, NJ 07417
www.bd.com

News Release



Contact:

Patricia A. Spinella, Investor Relations — 201-847-5453
Colleen T. White, Corporate Communications — 201-847-5369

BD ANNOUNCES RESULTS FOR FOURTH FISCAL QUARTER AND FULL YEAR

Franklin Lakes, NJ (November 4, 2009)— BD (Becton, Dickinson and Company) (NYSE: BDX) today reported quarterly revenues of \$1.898 billion for the fourth fiscal quarter ended September 30, 2009, representing an increase of 5 percent from the prior-year period, or 8 percent excluding the unfavorable impact from foreign currency translation.

For the full fiscal year ended September 30, 2009, BD reported revenues of \$7.161 billion, representing an increase of 1 percent over the prior year, or 5 percent excluding the unfavorable impact from foreign currency translation.

“The achievement of solid fourth quarter performance, in particular BD Medical and BD Diagnostics, marks the conclusion of another successful year for BD,” said Edward J. Ludwig, Chairman and Chief Executive Officer. “This strong finish to the year provides a platform for growth in fiscal 2010 and gives us confidence we will achieve our stated long-term goals.”

Fourth Quarter Earnings and Analysis of Full Fiscal Year 2009 and 2008 Earnings

Reported diluted earnings per share from continuing operations of \$1.25 for the fourth quarter of 2009 increased by 13 percent over reported diluted earnings per share from continuing operations of \$1.11 for the fourth quarter of 2008. On a currency-neutral basis, diluted earnings per share from continuing operations for the fourth quarter of fiscal 2009 increased 17 percent.

(Table 1)	Twelve Months Ended September 30,			
	FY2009	FY2008	% Change	FXN % Change
Diluted EPS from Continuing Operations:	\$ 4.92	\$ 4.42	11%	
Specified Items:				
Litigation Charge (1)	\$ 0.11			
Tax Adjustment (2)	(0.08)			
Adjusted Diluted EPS from Continuing Operations:	\$ 4.95	\$ 4.42	12%	10%

(1) Represents the charge relating to the pending settlement with the direct purchaser plaintiffs (which includes BD’s distributors) in the antitrust class actions.

(2) Represents the tax benefit relating to various tax settlements in multiple jurisdictions.

The preceding analysis (Table 1) of diluted earnings per share from continuing operations for the twelve-month periods ended September 30, 2009 and 2008 identifies the specified items that affect comparability of results between periods. As illustrated, fiscal year 2009 diluted earnings per share from continuing operations of \$4.92 included the third quarter tax benefit of 8 cents and the second quarter charge of 11 cents relating to a pending antitrust class action settlement. Excluding these specified items, diluted earnings per share from continuing operations for the twelve-month period in fiscal year 2009 were \$4.95, representing an increase of 12 percent over diluted earnings per share from continuing operations of \$4.42 from the prior-year period. On a currency-neutral basis, adjusted diluted earnings per share from continuing operations for the twelve-month period ending September 30, 2009 increased 10 percent.

Segment Results

In the BD Medical segment, worldwide revenues for the quarter were \$1 billion, representing an increase of 8 percent from the prior-year period, or 13 percent excluding the unfavorable impact from foreign currency translation. Strong sales of Pharmaceutical Systems products, as expected, and solid sales of Medical Surgical Systems products contributed to revenue growth; both included a favorable impact from flu-related sales. For the twelve-month period ended September 30, 2009, the BD Medical segment reported flat revenue growth. On a currency-neutral basis, BD Medical revenues for the twelve-month period increased by 6 percent to \$3.731 billion.

In the BD Diagnostics segment, worldwide revenues for the quarter were \$580 million, representing an increase of 5 percent from the prior-year period or 8 percent excluding the unfavorable impact from foreign currency translation. Sales of safety-engineered devices, cancer diagnostics products and infectious disease testing systems, including flu-related products, contributed to revenue growth. For the twelve-month period ended September 30, 2009, the BD Diagnostics segment reported 3 percent revenue growth to \$2.226 billion. On a currency-neutral basis, BD Diagnostics revenues for the twelve-month period increased by 7 percent.

In the BD Biosciences segment, worldwide revenues for the quarter were \$312 million, representing a decrease of 5 percent from the prior-year period, or a decrease of 4 percent excluding the unfavorable impact from foreign currency translation. Demand in the U.S. for capital equipment in the research and clinical segments continued to be impacted by funding constraints. International revenue growth continued to moderate as well. For the twelve-month period ended September 30, 2009, the BD Biosciences segment reported 1 percent revenue growth to \$1.204 billion. On a currency-neutral basis, BD Biosciences revenues for the twelve-month period increased by 2 percent.

Geographic Results

Fourth quarter revenues in the U.S. were \$840 million, representing an increase of 6 percent from the prior-year period. Revenues outside of the U.S. were \$1.058 billion, representing an increase of 4 percent from the prior-year period, or 10 percent excluding the unfavorable impact from foreign currency translation.

For the twelve-month period ended September 30, 2009, revenues in the U.S. were \$3.205 billion, representing an increase of 3 percent from the prior-year period. Revenues outside of the U.S. were \$3.956 billion, representing flat growth from the prior-year period, or 7 percent growth excluding the unfavorable impact from foreign currency translation.

Fiscal 2010 Outlook for Full Year

The Company estimates that reported revenues for the full fiscal year 2010 will increase about 6 percent, or 5 to 6 percent excluding the estimated favorable impact from foreign currency translation.

The Company expects diluted earnings per share from continuing operations for the full fiscal year 2010 to increase approximately 1 to 3 percent over adjusted diluted earnings per share from continuing operations, excluding specified items, of \$4.95 for the fiscal year 2009, or 7 to 9 percent excluding the estimated unfavorable impact from foreign currency translation.

Conference Call Information

A conference call regarding BD's fourth fiscal quarter and full year results and its expectations for fiscal year 2010 will be broadcast live on BD's website, www.bd.com/investors, along with related slides, at 10:00 a.m. (ET) Wednesday, November 4, 2009. The conference call will be available for replay through the close of business on November 11, 2009 on BD's website, www.bd.com/investors, or at 1-800-642-1687 (domestic) and 1-706-645-9291 (international), access code 34687454.

This news release contains certain non-GAAP financial measures. A reconciliation of these and other measures to the comparable GAAP measures is included in this release and in the attached financial tables, as well as in the Form 8-K that BD filed today with the SEC.

About BD

BD is a leading global medical technology company that develops, manufactures and sells medical devices, instrument systems and reagents. The Company is dedicated to improving people's health throughout the world. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines. BD's capabilities are instrumental in combating many of the world's most pressing diseases. Founded in 1897 and headquartered in Franklin Lakes, New Jersey, BD employs approximately 29,000 associates in approximately 50 countries throughout the world. The Company serves healthcare institutions, life science researchers, clinical laboratories, the pharmaceutical industry and the general public. For more information, please visit www.bd.com.

This press release, including the section entitled "Fiscal 2010 Outlook for Full Year," contains certain estimates and other forward-looking statements (as defined under Federal securities laws) regarding BD's performance, including future revenues, earnings per share and income, or events or developments that BD expects to occur or anticipates occurring in the future. All such statements are based upon current expectations of BD and involve a number of business risks and uncertainties. Actual results could vary materially from anticipated results described, implied or projected in any forward-looking statement. With respect to forward-looking statements contained herein, a number of factors could cause actual results to vary materially from any forward-looking statement. For instance, various healthcare reform proposals, if enacted, would impose an excise tax applicable to medical device manufacturers, including BD, and these may be effective in calendar year 2010. Other factors include, but are not limited to: adverse changes in regional, national or foreign economic conditions, including any impact that may result from the current global economic downturn on our ability to access credit markets and finance our operations, the demand for our products and services, or our suppliers' ability to provide products needed for our operations; changes in interest or foreign currency exchange rates, particularly in light of increased volatility in currency exchange rates; potential healthcare reform, including changes in government pricing and reimbursement policies or

other cost containment reforms; competitive factors; pricing and market share pressures; difficulties inherent in product development and delays in product introductions; increases in energy costs and their effect on, among other things, the cost of producing BD's products; fluctuations in costs and availability of raw materials and in BD's ability to maintain favorable supplier arrangements and relationships; uncertainties of litigation (as described in BD's filings with the Securities and Exchange Commission); the effects of potential pandemic diseases; our ability to successfully integrate any businesses we acquire; and issuance of new or revised accounting standards, as well as other factors discussed in BD's filings with the Securities and Exchange Commission. We do not intend to update any forward-looking statements to reflect events or circumstances after the date hereof except as required by applicable laws or regulations.

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	2009	Three Months Ended September 30, 2008	% Change
REVENUES	\$1,897,733	\$1,812,156	4.7
Cost of products sold	911,911	880,372	3.6
Selling and administrative	432,477	432,399	0.0
Research and development	113,737	108,463	4.9
TOTAL OPERATING COSTS AND EXPENSES	1,458,125	1,421,234	2.6
OPERATING INCOME	439,608	390,922	12.5
Interest income	14,418	6,879	NM
Interest expense	(13,782)	(8,889)	55.0
Other expense, net	(3,312)	(1,734)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	436,932	387,178	12.9
Income tax provision	131,175	108,216	21.2
INCOME FROM CONTINUING OPERATIONS	305,757	278,962	9.6
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$3,334 AND \$1,222, RESPECTIVELY	11,463	3,212	NM
NET INCOME	\$ 317,220	\$ 282,174	12.4
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 1.28	\$ 1.14	12.3
Income from discontinued operations	\$ 0.05	\$ 0.01	NM
Net income (1)	\$ 1.33	\$ 1.16	14.7
Diluted:			
Income from continuing operations	\$ 1.25	\$ 1.11	12.6
Income from discontinued operations	\$ 0.05	\$ 0.01	NM
Net income (1)	\$ 1.29	\$ 1.12	15.2
AVERAGE SHARES OUTSTANDING			
Basic	239,162	243,863	
Diluted	245,056	251,197	

NM — Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY
CONSOLIDATED INCOME STATEMENTS
(Unaudited; Amounts in thousands, except per share data)

	2009	Twelve Months Ended September 30, 2008	% Change
REVENUES	\$7,160,874	\$7,074,942	1.2
Cost of products sold	3,397,598	3,446,838	(1.4)
Selling and administrative	1,704,795	1,695,610	0.5
Research and development	408,128	395,631	3.2
TOTAL OPERATING COSTS AND EXPENSES	5,510,521	5,538,079	(0.5)
OPERATING INCOME	1,650,353	1,536,863	7.4
Interest income	33,148	39,368	(15.8)
Interest expense	(40,389)	(36,343)	11.1
Other expense, net	(3,850)	(1,484)	NM
INCOME FROM CONTINUING OPERATIONS BEFORE INCOME TAXES	1,639,262	1,538,404	6.6
Income tax provision	426,208	422,537	0.9
INCOME FROM CONTINUING OPERATIONS	1,213,054	1,115,867	8.7
INCOME FROM DISCONTINUED OPERATIONS NET OF INCOME TAX PROVISION OF \$5,014 AND \$2,585, RESPECTIVELY	18,549	11,129	NM
NET INCOME	\$1,231,603	\$1,126,996	9.3
EARNINGS PER SHARE			
Basic:			
Income from continuing operations	\$ 5.04	\$ 4.57	10.3
Income from discontinued operations	\$ 0.08	\$ 0.05	NM
Net income (1)	\$ 5.12	\$ 4.61	11.1
Diluted:			
Income from continuing operations	\$ 4.92	\$ 4.42	11.3
Income from discontinued operations	\$ 0.08	\$ 0.04	NM
Net income (1)	\$ 4.99	\$ 4.46	11.9
AVERAGE SHARES OUTSTANDING			
Basic	240,479	244,323	
Diluted	246,798	252,681	

NM — Not Meaningful

(1) Total per share amounts may not add due to rounding

BECTON DICKINSON AND COMPANY
 SUPPLEMENTAL REVENUE INFORMATION
 REVENUES BY SEGMENT AND GEOGRAPHIC AREA
 (Unaudited; Amounts in thousands)

	Three Months Ended September 30,		
	2009	2008	% Change
BD MEDICAL			
United States	\$ 410,925	\$ 374,487	9.7
International	594,573	555,109	7.1
TOTAL	\$1,005,498	\$ 929,596	8.2
BD DIAGNOSTICS			
United States	\$ 305,488	\$ 281,148	8.7
International	274,521	271,918	1.0
TOTAL	\$ 580,009	\$ 553,066	4.9
BD BIOSCIENCES			
United States	\$ 123,225	\$ 136,749	(9.9)
International	189,001	192,745	(1.9)
TOTAL	\$ 312,226	\$ 329,494	(5.2)
TOTAL REVENUES			
United States	\$ 839,638	\$ 792,384	6.0
International	1,058,095	1,019,772	3.8
TOTAL	\$1,897,733	\$1,812,156	4.7

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY SEGMENT AND GEOGRAPHIC AREA
(Unaudited; Amounts in thousands)

	Twelve Months Ended September 30,		
	2009	2008	% Change
BD MEDICAL			
United States	\$1,577,986	\$1,524,204	3.5
International	2,152,860	2,195,831	(2.0)
TOTAL	\$3,730,846	\$3,720,035	0.3
BD DIAGNOSTICS			
United States	\$1,177,543	\$1,121,843	5.0
International	1,048,676	1,037,968	1.0
TOTAL	\$2,226,219	\$2,159,811	3.1
BD BIOSCIENCES			
United States	\$ 449,151	\$ 470,641	(4.6)
International	754,658	724,455	4.2
TOTAL	\$1,203,809	\$1,195,096	0.7
TOTAL REVENUES			
United States	\$3,204,680	\$3,116,688	2.8
International	3,956,194	3,958,254	(0.1)
TOTAL	\$7,160,874	\$7,074,942	1.2

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30,
(Unaudited; Amounts in thousands)

	United States		% Change
	2009	2008	
BD MEDICAL			
Medical Surgical Systems	\$267,070	\$248,111	7.6
Diabetes Care	88,590	82,445	7.5
Pharmaceutical Systems	48,353	37,512	28.9
Ophthalmic Systems	6,912	6,419	7.7
TOTAL	\$410,925	\$374,487	9.7
BD DIAGNOSTICS			
Preanalytical Systems	\$156,328	\$145,987	7.1
Diagnostic Systems	149,160	135,161	10.4
TOTAL	\$305,488	\$281,148	8.7
BD BIOSCIENCES			
Cell Analysis	\$ 84,179	\$ 98,883	(14.9)
Discovery Labware	39,046	37,866	3.1
TOTAL	\$123,225	\$136,749	(9.9)
TOTAL UNITED STATES	\$839,638	\$792,384	6.0

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	International				
	2009	2008	Reported	% Change FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 265,904	\$ 261,190	1.8	11.0	(9.2)
Diabetes Care	92,098	92,593	(0.5)	5.1	(5.6)
Pharmaceutical Systems	224,195	188,773	18.8	26.7	(7.9)
Ophthalmic Systems	12,376	12,553	(1.4)	5.4	(6.8)
TOTAL	\$ 594,573	\$ 555,109	7.1	15.2	(8.1)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 138,297	\$ 141,119	(2.0)	5.5	(7.5)
Diagnostic Systems	136,224	130,799	4.1	8.7	(4.6)
TOTAL	\$ 274,521	\$ 271,918	1.0	7.0	(6.0)
BD BIOSCIENCES					
Cell Analysis	\$ 150,055	\$ 154,719	(3.0)	(0.3)	(2.7)
Discovery Labware	38,946	38,026	2.4	3.4	(1.0)
TOTAL	\$ 189,001	\$ 192,745	(1.9)	0.4	(2.3)
TOTAL INTERNATIONAL	\$1,058,095	\$1,019,772	3.8	10.2	(6.4)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Three Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	2009	2008	Total		
			Reported	% Change FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 532,974	\$ 509,301	4.6	9.3	(4.7)
Diabetes Care	180,688	175,038	3.2	6.2	(3.0)
Pharmaceutical Systems	272,548	226,285	20.4	27.1	(6.7)
Ophthalmic Systems	19,288	18,972	1.7	6.2	(4.5)
TOTAL	\$1,005,498	\$ 929,596	8.2	13.0	(4.8)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 294,625	\$ 287,106	2.6	6.3	(3.7)
Diagnostic Systems	285,384	265,960	7.3	9.5	(2.2)
TOTAL	\$ 580,009	\$ 553,066	4.9	7.8	(2.9)
BD BIOSCIENCES					
Cell Analysis	\$ 234,234	\$ 253,602	(7.6)	(6.0)	(1.6)
Discovery Labware	77,992	75,892	2.8	3.3	(0.5)
TOTAL	\$ 312,226	\$ 329,494	(5.2)	(3.8)	(1.4)
TOTAL REVENUES	\$1,897,733	\$1,812,156	4.7	8.4	(3.7)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30,
(Unaudited; Amounts in thousands)

	United States		% Change
	2009	2008	
BD MEDICAL			
Medical Surgical Systems	\$1,021,846	\$ 977,262	4.6
Diabetes Care	351,618	332,545	5.7
Pharmaceutical Systems	177,529	189,394	(6.3)
Ophthalmic Systems	26,993	25,003	8.0
TOTAL	\$1,577,986	\$1,524,204	3.5
BD DIAGNOSTICS			
Preanalytical Systems	\$ 608,754	\$ 574,378	6.0
Diagnostic Systems	568,789	547,465	3.9
TOTAL	\$1,177,543	\$1,121,843	5.0
BD BIOSCIENCES			
Cell Analysis	\$ 303,846	\$ 324,698	(6.4)
Discovery Labware	145,305	145,943	(0.4)
TOTAL	\$ 449,151	\$ 470,641	(4.6)
TOTAL UNITED STATES	\$3,204,680	\$3,116,688	2.8

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	International				
	2009	2008	Reported	% Change FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$ 963,083	\$1,027,592	(6.3)	4.5	(10.8)
Diabetes Care	363,319	361,807	0.4	7.9	(7.5)
Pharmaceutical Systems	774,914	752,742	2.9	10.9	(8.0)
Ophthalmic Systems	51,544	53,690	(4.0)	4.1	(8.1)
TOTAL	\$2,152,860	\$2,195,831	(2.0)	7.2	(9.2)
BD DIAGNOSTICS					
Preanalytical Systems	\$ 534,677	\$ 549,150	(2.6)	6.8	(9.4)
Diagnostic Systems	513,999	488,818	5.2	11.2	(6.0)
TOTAL	\$1,048,676	\$1,037,968	1.0	8.9	(7.9)
BD BIOSCIENCES					
Cell Analysis	\$ 600,671	\$ 575,813	4.3	5.9	(1.6)
Discovery Labware	153,987	148,642	3.6	4.2	(0.6)
TOTAL	\$ 754,658	\$ 724,455	4.2	5.5	(1.3)
TOTAL INTERNATIONAL	\$3,956,194	\$3,958,254	(0.1)	7.4	(7.5)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
REVENUES BY BUSINESS SEGMENTS AND UNITS
Twelve Months Ended September 30, (continued)
(Unaudited; Amounts in thousands)

	2009	2008	Total		
			Reported	% Change FX Neutral	FX Impact
BD MEDICAL					
Medical Surgical Systems	\$1,984,929	\$2,004,854	(1.0)	4.5	(5.5)
Diabetes Care	714,937	694,352	3.0	6.8	(3.8)
Pharmaceutical Systems	952,443	942,136	1.1	7.4	(6.3)
Ophthalmic Systems	78,537	78,693	(0.2)	5.3	(5.5)
TOTAL	\$3,730,846	\$3,720,035	0.3	5.7	(5.4)
BD DIAGNOSTICS					
Preanalytical Systems	\$1,143,431	\$1,123,528	1.8	6.4	(4.6)
Diagnostic Systems	1,082,788	1,036,283	4.5	7.4	(2.9)
TOTAL	\$2,226,219	\$2,159,811	3.1	6.8	(3.7)
BD BIOSCIENCES					
Cell Analysis	\$ 904,517	\$ 900,511	0.4	1.4	(1.0)
Discovery Labware	299,292	294,585	1.6	1.9	(0.3)
TOTAL	\$1,203,809	\$1,195,096	0.7	1.5	(0.8)
TOTAL REVENUES	\$7,160,874	\$7,074,942	1.2	5.4	(4.2)

BECTON DICKINSON AND COMPANY
SUPPLEMENTAL REVENUE INFORMATION
SAFETY REVENUES
(Unaudited; Amounts in thousands)

	Three Months Ended September 30,				
	2009	2008	% Change		
			Reported	FX Neutral	FX Impact
TOTAL SAFETY REVENUES					
United States	\$282,286	\$261,007	8.2	8.2	—
International	150,906	143,258	5.3	13.5	(8.2)
TOTAL	\$433,192	\$404,265	7.2	10.0	(2.8)
BY SEGMENT:					
BD Medical	\$211,049	\$191,813	10.0	12.1	(2.1)
BD Diagnostics	222,143	212,452	4.6	8.1	(3.5)
TOTAL	\$433,192	\$404,265	7.2	10.0	(2.8)

	Twelve Months Ended September 30,				
	2009	2008	% Change		
			Reported	FX Neutral	FX Impact
TOTAL SAFETY REVENUES					
United States	\$1,079,000	\$1,035,615	4.2	4.2	—
International	570,674	534,055	6.9	17.3	(10.4)
TOTAL	\$1,649,674	\$1,569,670	5.1	8.6	(3.5)
BY SEGMENT:					
BD Medical	\$ 786,033	\$ 748,722	5.0	7.7	(2.7)
BD Diagnostics	863,641	820,948	5.2	9.5	(4.3)
TOTAL	\$1,649,674	\$1,569,670	5.1	8.6	(3.5)

Fourth Quarter Fiscal Year 2009 Reconciliations

	Actual FY 2009	Actual FY 2008	Reported Change Fav (Unfav.)	Foreign Currency Translation	Hedge Gain	Total FX	FXN Change ⁽¹⁾	FXN Growth
Revenue	\$ 1,898	\$ 1,812	86	(77)	11	(66)	152	8.4%
Gross Profit	986	932	54	(49)	11	(38)	92	9.8%
% of Revenue	51.9%	51.4%						
SSG &A	432	432	-	16	-	16	(16)	-3.8%
% of Revenue	22.8%	23.9%						
R&D	114	108	(5)	1	-	1	(6)	-6.0%
% of Revenue	6.0%	6.0%						
Operating Income	\$ 440	\$ 391	49	(31)	11	(20)	69	17.6%
% of Revenue	23.2%	21.6%						
Income Tax	131	108	(23)	11	(4)	7	(30)	-27.3%
Effective Tax Rate	30.0%	27.9%						
Income from Continuing Operations	306	279	27	(20)	7	(13)	40	14.4%
% of Revenue	16.1%	15.4%						
EPS	\$ 1.25	1.11	0.14	(0.08)	0.03	(0.05)	0.19	17.1%

⁽¹⁾ Represents the reported change excluding foreign currency translation impact and associated hedging gains.
Note: All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

1



Fiscal Year 2009 Reconciliations

	Reported FY 2009	Specified Items		Adjusted FY 2009	Actual FY 2008	Adjusted Change Fav (Unfav.)	Foreign Currency Translation ⁽³⁾	Hedge Gain	Total FX	Adjusted FXN Change ⁽⁴⁾	FXN Growth
		Litigation Charge ⁽¹⁾	Tax ⁽²⁾								
Revenue	\$ 7,161			\$ 7,161	\$ 7,075	86	(398)	105	(293)	379	5.4%
Gross Profit	3,763			3,763	3,628	135	(159)	105	(54)	189	5.2%
% of Revenue	52.6%			52.6%	51.3%						
SSG&A	1,705	(45)		1,660	1,696	36	84	-	84	(48)	-2.9%
% of Revenue	23.8%			23.2%	24.0%						
R&D	408			408	396	(12)	7	-	7	(20)	-5.0%
% of Revenue	5.7%			5.7%	5.6%						
Operating Income	\$ 1,650	(45)		\$ 1,695	\$ 1,537	158	(67)	105	38	121	7.8%
% of Revenue	23.0%			23.7%	21.7%						
Income Tax	426		17 20	464	423	(41)	26	(40)	(14)	(28)	-6.5%
Effective Tax Rate	26.0%			27.5%	27.5%						
Income from Continuing Operations	\$ 1,213		28 (20)	\$ 1,220	\$ 1,116	105	(39)	65	26	79	7.1%
% of Revenue	16.9%			17.0%	15.8%						
EPS	\$ 4.92	0.11	(0.08)	\$ 4.95	\$ 4.42	\$ 0.53	(0.16)	0.26	0.10	0.43	9.7%

(1) Represents the charge relating to the pending settlement with the direct purchaser plaintiffs (which include a BD's distributors) in the antitrust class actions.

(2) Represents the tax benefit relating to various tax settlements in multiple jurisdictions.

(3) Includes first quarter foreign currency; holding gain of \$3.5M or \$0.05 per diluted share.

(4) Represents the adjusted reported change including foreign currency; translation impact and associated hedging gains.

Note: All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.